

2. RESPONSE/REMARKS

2.1 STATUS OF THE CLAIMS

Claims 1-25 were pending at the time of the Action, and subject to elections of species.

Claims 26-28 have been added herein.

Claims 1, 6-20, 22, and 25-28 read on the elected species; claims 1, 6-20, 22, and 25-26 are generic.

Claims 1-28 are now pending in the case, and ready for initial examination on the merits.

2.2 SUPPORT FOR THE AMENDMENT

The pending claims are fully supported by the original specification and claims as filed.

Applicants certify no new matter is included by entry of the present amendment.

2.3 ELECTION OF SPECIES

The Action at page 2 requires Applicants to make an election of species for examination on the merits. The required elections are as follows:

(i) inhibitor of a G protein-coupled receptor wherein:

A, B, C, D, E, F, X, R, and n are specified

(ii) a second agent for treating a hypersensitivity condition; and

(iii) a hypersensitivity condition.

For their first species election, Applicants hereby elect, *without traverse*, the inhibitor of G protein coupled receptor having the formula “AcF[OPdChaWR]” in which the variables of the general formula are as follows:

A is NH-acyl;
B is the side chain of L-phenylalanine;
C is the side chain of L-proline;
D is the side chain of D-cyclohexylalanine;
E is the side chain of L-tryptophan;
F is the side chain of L-arginine; and
X is $-(\text{CH}_2)_3-$.

(when X is $-(\text{CH}_2)_3-$, *n* need not be defined).

This species of inhibitor is also known as “PMX53” (see claim 14).

For their second species election, Applicants hereby elect, *without traverse*, “infliximab” as the second agent for treating a hypersensitivity condition (see claim 16).

For their third species election, Applicants hereby elect, *without traverse*, “dermatitis” as the hypersensitivity condition (see claim 19).

Applicants respectfully request that initial examination on the merits now commence with respect to the pending claims. New claims 26-28 have been added to read specifically on the three elections imposed by the Office.

2.5 CONCLUSION

Applicants believe that the present paper is fully responsive to the pending Action, and further believe that the pending claims are acceptable under all sections of the Statutes and are in conditions for initial examination on the merits. Should Examiner Zarek have any questions, a telephone call to the Applicants' undersigned representative would be appreciated.

Respectfully submitted,




Mark D. Moore, Ph.D.
Registration No. 42,903

Date: October 8, 2008
HAYNES AND BOONE, LLP
Customer No. 27683
Telephone: 713-547-2040
Facsimile: 214-200-0853

Certificate of Service

I hereby certify that this correspondence is being filed with the U.S. Patent and Trademark Office via EFS-Web on October 8, 2008.



Margaret A. Pruitt

H-748858v1